KRX •
Healthcare •
Biotechnology •
Quote as of 10/28/2026 15:30
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeKRX
Market Capitalization55,631,368 mln
Float11.89 mln
Earnings Date10/28/2026
EPS
42,900
Exceptional
P / E
31.93
Overvalued
Piotroski F-Score
8
/ 9
Very strong
Beneish M-Score
-3.13
Reliable
1-Year Forecast
1,899,600
Strong upside
Relative Strength
98
/ 100
Top performer
Business Description
Samsung Biologics, founded in 2011 and based in Incheon, South Korea, produces and delivers biopharmaceutical products to clients across South Korea, Europe, the United States, and other global markets. The company supports drug development from early research through to finished product, offering services such as cell line development, manufacturing, quality testing, and cold chain logistics. It also develops and manufactures specialized therapies including antibody-drug conjugates and mRNA-based products.
